Christopher James Turns a Clinical Eye on Biotechs with High Reward Potential
Source: George S. Mack of The Life Sciences Report  (7/31/14)
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed risk hold a short list of companies with huge potential. James, a senior analyst and managing director at Brinson Patrick Securities, is a neurosurgeon by training, and examines new platforms and proposed therapies with a clinician's eye. In this interview with The Life Sciences Report, James turns that eye on three names with dramatic, paradigm-changing technology platforms that could energize portfolios. More >

Is It Bad to Bottle Up Your Anger?
Source: Claudia Hammond, BBC  (7/30/14)
"Even if studies are inconclusive as to whether getting angry is always good for us physically, surely the mere act of letting it all out will provide some relief, won't it? Maybe not." More >

ROTH Capital's Debjit Chattopadhyay: Marriage of Diagnostics to New Therapies Breeds Biotech Winners
Source: Dan Levy of The Life Sciences Report  (7/24/14)
Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners recommends that biotech investors consider these trends when looking at portfolio options in the healthcare sector. A medical researcher turned biotech analyst, Chattopadhyay highlights several companies with unique diagnostic and therapeutic technologies in this interview with The Life Sciences Report. More >

Tempering Insane Optimism with Due Diligence: Alan Leong on Niche Biotech Prospects
Source: George S. Mack of The Life Sciences Report  (7/17/14)
Alan Leong has chosen to look for investments positioned in less obvious alcoves of the market. Interestingly, this concept could be a competitive advantage for retail investors. His niche markets include orphan, metabolic and animal companion medicine, as well as some less obvious indications for regenerative medicine. In this interview with The Life Sciences Report, the CEO of biotech analysis company BioWatch News cites four unconventional biotech and specialty pharma names positioned to generate significant returns for investors. More >

Dial In on Diabetes Solutions with LabStyle Innovations Corp.'s Dario
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (7/17/14)
Having a chronic disease like diabetes engenders a sense of isolation that hasn't been adequately addressed by technology until now. With Dario, LabStyle Innovations Corp. has created a device that not only provides vital medical information to a diabetic patient in real time, but also connects that patient to a community of care providers, family and online resources. In this interview with The Life Sciences Report, LabStyle President and CEO Erez Raphael describes how the Dario software platform could provide sufferers of other chronic diseases with the benefits of real-time data and community as well. More >

Will New Technology Make You Love Going to the Dentist?
Source: Stephen Petranek, Daily Reckoning  (7/14/14)
"Dentistry is ripe for high-tech blockbusters." More >

Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners
Source: George S. Mack of The Life Sciences Report  (7/10/14)
The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall. In this interview with The Life Sciences Report, Benjamin showcases names with powerful platforms and market winds to their backs, which he believes could vigorously multiply investor capital over the next 12–18 months. More >

Into Record-Setting Territory: Huge Q2 for Biotech and Pharma M&A
Source: Amy Brown, EP Vantage   (7/9/14)
"The stampede of U.S. companies seeking shelter from the country’s high domestic corporation tax rate has largely driven the deal making. This financial engineering has been widely applauded by the markets but has increasingly been raising the ire of politicians." More >

Bubble? What Bubble? The BioScience Profit Outlook for the Rest of 2014
Source: Ernie Tremblay, Money Morning  (7/2/14)
"Bioscience investors are putting their money into companies making good drugs with solid data that meet critical needs in the real world. They're helping fuel R&D into terrible and terrifying diseases, and they're funding the distribution of those products into a waiting market." More >

Healthcare Sector Spurred by Population Growth and M&As
Source: Frank Holmes, U.S. Global Investors  (6/27/14)
"The recent trend in healthcare M&As has many benefits, not least of which is the ability to reach a wider range of people who depend on the drugs and treatments the industry delivers." More >

Piper Jaffray's Charles Duncan Addresses Pot Shots
Source: George S. Mack of The Life Sciences Report  (6/26/14)
Early-stage biotech is a risky investment, but some bets are safer than others. Inovio Pharmaceuticals Inc. is doing high-stakes experimental work in both preventive and therapeutic medicine, addressing HIV, cancers and pre-cancers. The company's lead clinical program is in Phase 2 and a data readout is imminent, which has made the stock both volatile and an easy target for critics. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Managing Director Charles Duncan of Piper Jaffray & Co. addresses some of the criticisms that overhang the stock. More >

Three Ways to Spot Bad Biotech Data
Source: BioMed Reports   (6/20/14)
"Biotech is (for the most part) a game of chance that has a lot to do with luck. However, I do believe that investors can significantly improve their chances of a win with just a rudimentary understanding of clinical trial data and how it is viewed by doctors and the FDA." More >

Fire Up the Immuno-Oncology Powerhouses: John McCamant
Source: Editors, The Life Sciences Report  (6/19/14)
Forecasting when we'll have a cure for cancer remains beyond the predictive powers of researchers and investors. But forecasting the focus of the latest American Society of Clinical Oncology meeting was in the cards: Immuno-oncology took center stage. In this interview with The Life Sciences Report, Medical Technology Stock Newsletter editor John McCamant describes the excitement surrounding this rapidly evolving sector, and names big pharma and small biotech players conjuring potential game-changers. More >

Two Cancer Stocks Take Shots on Goal: Echo He
Source: George S. Mack of The Life Sciences Report  (6/19/14)
Oncology is king in biotech. Patients must be put on one drug, and then another, followed by another, as the disease progresses and becomes resistant. Multiple drugs will always be necessary, meaning multiple opportunities for drug companies. In this interview with The Life Sciences Report, analyst Echo He, formerly with the Maxim Group, serves investors two cancer drug picks that have been battered but are hot for a comeback. More >

The LifeSci Startup with 'The Ultimate App'
Source: Stephen Petranek, The Daily Reckoning   (6/17/14)
"What if when you went into a grocery store, a smartphone app could tell you which foods you were about to purchase might make your specific body sick—or which might prevent illness?" More >

Stunning Potential for Upside in Canadian Biotech: Brian Bloom
Source: George S. Mack of The Life Sciences Report  (6/12/14)
You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling skill sets and pipelines. In this interview with The Life Sciences Report, Bloom talks about his firm's upcoming conference and presents a detailed picture of four very interesting companies that could return doubles, triples or more. More >

Immunopalooza! Time to Profit (Again) from the 'ASCO Effect'
Source: William Patalon, Money Morning  (6/12/14)
"Investors like us love ASCO because of the so-called 'ASCO Effect'—a hefty surge in cancer-focused biotech stocks that always accompanies the start of this meeting." More >

Silver: The Undercover Super Metal Does Medicine, Too
Source: Visual Capitalist  (6/12/14)
"Silver plays a major roll in technology today. From everyday gadgets to healing wounds, this precious is an important part of modern life." More >

Shortage of R&D at Big Pharma Creates Demand for Small Biotech: Joseph Pantginis
Source: George S. Mack of The Life Sciences Report  (6/5/14)
The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview with The Life Sciences Report, ROTH Capital Partners' Senior Research Analyst Joseph Pantginis presents five biotech names with varying timeframes for market-moving data that could provide huge upside for investors willing to do some homework and understand the growth proposition. More >

Focus on Catalysts to Cash In on Biotech: Jason Kolbert
Source: George S. Mack of The Life Sciences Report  (6/4/14)
When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The Maxim Group's Senior Managing Director and Head of Healthcare Jason Kolbert lives by catalysts, and urges his investor clientele to understand there is no other reason to buy a stock except in anticipation of new information that creates value. In this interview with The Life Sciences Report, Kolbert discusses six names that have immense regenerative power for portfolios. More >

ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn
Source: George S. Mack of The Life Sciences Report  (5/28/14)
Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1. Participants have submitted abstracts for promising therapies in advance of the conference, profiling new compounds that could lead to better outcomes for patients and bolster the health of investment portfolios. In this interview with The Life Sciences Report, LifeTech Capital's Stephen Dunn walks us through some of the highlights. More >

Turn Solid Gold into Biotech Gold with James West
Source: Peter Byrne of The Life Sciences Report  (5/28/14)
The globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space. In this interview with The Life Sciences Report, James West points to low-hanging biofruit ripe for the picking. More >

Harnessing the Power of Nature's Perfect Cells: Robert J. Hariri
Source: George S. Mack of The Life Sciences Report  (5/22/14)
Neurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report. Hariri also discusses the special nature and advantages of placenta-derived stem cells, and an elegant solution to the scourge of muscle wasting in late-stage disease and advancing age that could apply to treatment of cardiovascular disease in the future. More >

The Naysayers Are Wrong: Rohit Vanjani on How You Can Make Money with Generics and Diagnostics
Source: George S. Mack of The Life Sciences Report  (5/22/14)
The concept that generic and specialty pharmaceutical drugs cannot command pricing power and growth is a misunderstanding, according to Director and Senior Analyst Rohit Vanjani of Oppenheimer and Co. Diagnostics also offer upside to investors: In fact, some recent returns disprove misconceptions in a spectacular fashion. The secret to making excellent margins in generics is to find markets where a vacuum has been created and product safety can be assured. The trick with diagnostics is to offer new tests that save steps, increase accuracy and reduce the burden on payers. In this interview with The Life Sciences Report, Vanjani discusses three names that fit the bill for investors seeking powerful growth in not-so-obvious sectors. More >

New Wave of M&A: Divestitures, Swaps and Inversions
Source: Andrew Forman, EY Life Sciences Blog  (5/22/14)
"This latest quarter, which kicks off a third year of negative growth, seems to have been the tipping point for pharma companies to finally emerge from a long M&A hibernation." More >